APA (7th ed.) Citation

Sarfaraz K. Niazi. (2024). Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven. MDPI AG.

Chicago Style (17th ed.) Citation

Sarfaraz K. Niazi. Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven. MDPI AG, 2024.

MLA (9th ed.) Citation

Sarfaraz K. Niazi. Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven. MDPI AG, 2024.